The FDA has approved Eccogene's IND application to commence a phase I trial of the company's thyroid hormone receptor (THR) agonist ECC-4703 in the U.S.
Cambridge Enterprise and European Molecular Biology Laboratory have presented new peptides derived from full-length factor V (FV) protein acting as T-cell activation inhibitors reported to be useful for the treatment of inflammatory bowel disease, type 1 diabetes, systemic lupus erythematosus, psoriasis, vasculitis, idiopathic pulmonary fibrosis, vitiligo and lupus nephritis, among other disorders.
According to a new study published in the July 27, 2022, issue of ScienceTranslationalMedicine, a lower intake of fermentable carbohydrates produces changes in the intestinal microbiota that decrease histamine production reducing chronic abdominal pain in patients with irritable bowel syndrome.
According to a new study published in the July 27, 2022, issue of ScienceTranslationalMedicine, a lower intake of fermentable carbohydrates produces changes in the intestinal microbiota that decrease histamine production reducing chronic abdominal pain in patients with irritable bowel syndrome (IBS).
Verve Therapeutics Inc. has packed a lot into the past few weeks. The latest is a four-year research deal with Vertex Pharmaceuticals Inc. to find and develop an in vivo gene editing program for an undisclosed liver disease. Vertex will pick up the tab for program costs as Verve does the preclinical R&D. Verve is getting an up-front $60 million from Vertex, along with a $35 million equity investment.
Microbiome specialist Enterome SA has out-licensed its lead human hormone mimetic, EM-1010, to Nestlé Health Sciences SA, in a deal that underlines the potential of its approach to generating novel drugs from proteins expressed by gut bacteria. EM-1010, the first program derived from Enterome’s Endomimics platform, is an orally available molecule that acts by promoting local release of interleukin 10 in the gut, with the aim of reducing inflammation. It is in development for the treatment of inflammatory bowel disease and food allergies and due to enter clinical trials in 2023.
Using long-term in vivo imaging combined with computational modeling, a multinational team of researchers has gained new insights into what makes potential stem cells able to fulfill their role functionally.
RSS
